vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Inogen Inc (INGN). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $68.6M, roughly 2.6× Inogen Inc). On growth, Inogen Inc posted the faster year-over-year revenue change (3.4% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-1.9M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 4.2%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
AVNS vs INGN — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $68.6M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | 51.4% |
| Operating Margin | 1.4% | -13.6% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | 3.4% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $68.6M | ||
| Q3 25 | $177.8M | $79.1M | ||
| Q2 25 | $175.0M | $79.2M | ||
| Q1 25 | $167.5M | $68.5M | ||
| Q4 24 | $179.6M | $66.3M | ||
| Q3 24 | $170.4M | $74.9M | ||
| Q2 24 | $171.7M | $74.4M | ||
| Q1 24 | $166.1M | $63.1M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-5.3M | ||
| Q2 25 | $-76.8M | $-4.2M | ||
| Q1 25 | $6.6M | $-6.2M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $-6.0M | ||
| Q2 24 | $1.8M | $-5.6M | ||
| Q1 24 | $-900.0K | $-14.6M |
| Q4 25 | 47.5% | 51.4% | ||
| Q3 25 | 48.4% | 52.2% | ||
| Q2 25 | 52.6% | 52.2% | ||
| Q1 25 | 53.6% | 53.1% | ||
| Q4 24 | 54.6% | 54.7% | ||
| Q3 24 | 54.5% | 55.2% | ||
| Q2 24 | 55.7% | 57.4% | ||
| Q1 24 | 57.1% | 54.5% |
| Q4 25 | 1.4% | -13.6% | ||
| Q3 25 | 0.1% | -9.0% | ||
| Q2 25 | -42.6% | -7.7% | ||
| Q1 25 | 6.1% | -11.2% | ||
| Q4 24 | -233.0% | -17.2% | ||
| Q3 24 | 7.0% | -10.4% | ||
| Q2 24 | 3.7% | -9.5% | ||
| Q1 24 | 2.4% | -25.8% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -6.7% | ||
| Q2 25 | -43.9% | -5.2% | ||
| Q1 25 | 3.9% | -9.0% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | -8.0% | ||
| Q2 24 | 1.0% | -7.5% | ||
| Q1 24 | -0.5% | -23.1% |
| Q4 25 | $-0.02 | $-0.26 | ||
| Q3 25 | $-0.03 | $-0.20 | ||
| Q2 25 | $-1.66 | $-0.15 | ||
| Q1 25 | $0.14 | $-0.25 | ||
| Q4 24 | $-8.64 | $-0.41 | ||
| Q3 24 | $0.09 | $-0.25 | ||
| Q2 24 | $0.04 | $-0.24 | ||
| Q1 24 | $-0.02 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $103.7M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $192.2M |
| Total Assets | $1.1B | $298.6M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $103.7M | ||
| Q3 25 | $70.5M | $106.5M | ||
| Q2 25 | $90.3M | $103.7M | ||
| Q1 25 | $97.0M | $118.9M | ||
| Q4 24 | $107.7M | $113.8M | ||
| Q3 24 | $89.0M | $105.7M | ||
| Q2 24 | $92.2M | $97.9M | ||
| Q1 24 | $75.8M | $107.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $192.2M | ||
| Q3 25 | $778.0M | $197.2M | ||
| Q2 25 | $776.3M | $199.5M | ||
| Q1 25 | $839.4M | $198.0M | ||
| Q4 24 | $828.5M | $173.9M | ||
| Q3 24 | $1.2B | $185.4M | ||
| Q2 24 | $1.2B | $187.6M | ||
| Q1 24 | $1.2B | $191.9M |
| Q4 25 | $1.1B | $298.6M | ||
| Q3 25 | $1.1B | $307.0M | ||
| Q2 25 | $1.0B | $312.0M | ||
| Q1 25 | $1.1B | $308.4M | ||
| Q4 24 | $1.2B | $296.2M | ||
| Q3 24 | $1.7B | $306.2M | ||
| Q2 24 | $1.7B | $308.9M | ||
| Q1 24 | $1.7B | $315.6M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-943.0K |
| Free Cash FlowOCF − Capex | $21.3M | $-1.9M |
| FCF MarginFCF / Revenue | 11.8% | -2.8% |
| Capex IntensityCapex / Revenue | 3.8% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-13.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-943.0K | ||
| Q3 25 | $14.0M | $2.2M | ||
| Q2 25 | $6.8M | $4.3M | ||
| Q1 25 | $25.7M | $-16.8M | ||
| Q4 24 | $57.9M | $-3.0M | ||
| Q3 24 | $23.0M | $7.0M | ||
| Q2 24 | $27.8M | $6.7M | ||
| Q1 24 | $-8.0M | $-4.7M |
| Q4 25 | $21.3M | $-1.9M | ||
| Q3 25 | $7.0M | $1.6M | ||
| Q2 25 | $-4.2M | $3.7M | ||
| Q1 25 | $19.0M | $-17.1M | ||
| Q4 24 | $53.1M | $-3.3M | ||
| Q3 24 | $20.0M | $5.3M | ||
| Q2 24 | $21.9M | $6.6M | ||
| Q1 24 | $-12.1M | $-6.1M |
| Q4 25 | 11.8% | -2.8% | ||
| Q3 25 | 3.9% | 2.0% | ||
| Q2 25 | -2.4% | 4.6% | ||
| Q1 25 | 11.3% | -24.9% | ||
| Q4 24 | 29.6% | -5.0% | ||
| Q3 24 | 11.7% | 7.1% | ||
| Q2 24 | 12.8% | 8.9% | ||
| Q1 24 | -7.3% | -9.6% |
| Q4 25 | 3.8% | 1.4% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 0.4% | ||
| Q4 24 | 2.7% | 0.5% | ||
| Q3 24 | 1.8% | 2.2% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
INGN
Segment breakdown not available.
